SML3154

Topiroxostat

≥98% (HPLC)

• 別名: 4-[3-(4-Pyridinyl)-1H-1,2,4-triazol-5-yl]-2-pyridinecarbonitrile, 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile, 5-(2-Cyano-4-pyridyl)-3-(4-pyridyl)-1,2,4-triazole, FYX 051, FYX-051
• 実験式（ヒル表記法）: C₁₃H₈N₆
• CAS番号: 577778-58-6
• 分子量: 248.24
• MDL番号: MFCD17167057
• UNSPSCコード: 51111800
• NACRES: NA.77

特性

• 品質水準: 100
• アッセイ: ≥98% (HPLC)
• フォーム: powder
• 色: white to beige
• 溶解性: DMSO: 2 mg/mL, clear (warmed)
• 保管温度: 2-8°C
• SMILES記法: N#CC1=NC=CC(C2=NNC(C3=CC=NC=C3)=N2)=C1
• InChI: 1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)
• InChI Key: UBVZQGOVTLIHLH-UHFFFAOYSA-N

詳細

生物化学的／生理学的作用

Topiroxostat (FYX-051) is an orally active and potent inhibitor of xanthine oxidoreductase (XOR). It appears that inhibition of XOR by topiroxostat is due to the formation a covalent linkage to molybdenum via oxygen in the hydroxylation reaction intermediate. Also, topiroxostat displayed a potent, non-covalent inhibition of XOR. It is approved for the treatment of gout and hyperuricemia in Japan.

安全性情報

• 保管分類コード: 11 - Combustible Solids
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable